Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...
Patients and Methods: Patients with metastatic RCC were infused daily with MGd 5 mg/kg on days 1-5 and days 15-19 of each 28-day cycle. Patients were evaluated for response on days 21-28 of every ...
Hosted on MSN1mon
EC conditionally approves MSD’s Welireg for VHL disease and RCCThe second is for adults with advanced clear cell RCC that has advanced after two or more lines of therapy, including a programmed death-ligand 1 inhibitor or a programmed death receptor-1 and a ...
Hosted on MSN16d
Former Park Authority Employee Named RCC's New Deputy Director“I am honored to take on this new role,” Baglini said, in an RCC release. “Through my work in various environments, including community centers, recreation facilities, rental venues and ...
Results from a phase 1 study presented Saturday showed that a 100 mg/day dose of casdatifan produced clinically meaningful responses in a third of patients previously treated for clear cell renal ...
Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback